DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION

CDRH PREMARKET REVIEW SUBMISSION COVER SHEET

Form Approval OMB No. 9010-0120

Expiration Date: September 30, 2004.

See OMB Statement on page 5. Date of Submission User Fee Payment ID Number FDA Submission Document Number (if known) **SECTION A** TYPE OF SUBMISSION **PMA & HDE Supplement** 510(k) **PMA PDP** Meeting Original Submission Regular (120 day) Original PDP Original Submission: Pre-510(K) Meeting Premarket Report Special Notice of Completion Traditional Pre-IDE Meeting Panel Track (PMA Only) Amendment to PDP Pre-PMA Meeting Modular Submission Special Abbreviated (Complete section I, Page 5) Amendment 30-day Supplement Pre-PDP Meeting Report 30-day Notice Day 100 Meeting Additional Information Report Amendment] 135-day Supplement Agreement Meeting Third Party Licensing Agreement Real-time Review Determination Meeting Amendment to PMA & HDE Supplement Other (specify): Other IDE **Humanitarian Device Class II Exemption Petition Evaluation of Automatic** Other Submission **Exemption (HDE)** Class III Designation (De Novo) Original Submission Original Submission Original Submission 513(g) Original Submission Other Amendment Amendment Additional Information Additional Information (describe submission): Supplement Supplement Report Report Amendment Have you used or cited Standards in your submission? Yes ☐ No (If Yes, please complete Section I, Page 5) SUBMITTER, APPLICANT OR SPONSOR **SECTION B** Company / Institution Name Establishment Registration Number (if known) Division Name (if applicable) Phone Number (including area code) Street Address FAX Number (including area code) State / Province ZIP/Postal Code City Country Contact Name Contact Title Contact E-mail Address APPLICATION CORRESPONDENT (e.g., consultant, if different from above) **SECTION C** Company / Institution Name Division Name (if applicable) Phone Number (including area code) Street Address FAX Number (including area code) State / Province ZIP/Postal Code City Country Contact Name Contact Title Contact E-mail Address

| SECTION D1 REA | SON FOR APPLICATION - PMA, PDP, OR H | DE |
|---|---|--|
| Withdrawal Additional or Expanded Indications Request for Extension Post-approval Study Protocol Request for Applicant Hold Request for Removal of Applicant Hold Request to Remove or Add Manufacturing Site Process change: Manufacturing Sterilization Packaging Other (specify below) Response to FDA correspondence: | Change in design, component, or specification: Software / Hardware Color Additive Material Specifications Other (specify below) Labeling change: Indications Instructions Performance Shelf Life Trade Name Other (specify below) | □ Location change: □ Manufacturer □ Sterilizer □ Packager □ Report Submission: □ Annual or Periodic □ Post-approval Study □ Adverse Reaction □ Device Defect □ Amendment □ Change in Ownership □ Change of Applicant Address |
| Other Reason (specify): | | |
| SECTION D2 | REASON FOR APPLICATION - IDE | |
| New Device New Indication Addition of Institution Expansion / Extension of Study IRB Certification Termination of Study Withdrawal of Application Unanticipated Adverse Effect Notification of Emergency Use Compassionate Use Request Treatment IDE Continued Access | Change in: Correspondent / Applicant Design / Device Informed Consent Manufacturer Manufacturing Process Protocol - Feasibility Protocol - Other Sponsor Report submission: Current Investigator Annual Progress Report Site Waiver Report | Repose to FDA Letter Concerning: Conditional Approval Deemed Approved Deficient Final Report Deficient Progress Report Deficient Investigator Report Disapproval Request Extension of Time to Respond to FDA Request Hearing |
| Other Reason (specify): | | |
| SECTION D3 | REASON FOR SUBMISSION - 510(k) | |
| New Device | Additional or Expanded Indications | Change in Technology |
| Other Reason (specify): | | |

FORM FDA 3514 (12/03) PAGE 2 OF 5 PAGES

| | TION E | whi | ADDIT ich substantial equivale | | NAL INFORMATI | ON ON 5 | 10(| K) SUE | 3MI | SSION | Summary of, or statement concerning, |
|---|--|-------|--------------------------------|-------|----------------------|------------------------|-----|--|--------------|---------|--------------------------------------|
| 1 | 21 codes of devices to | 2 | | 1100 | 3 | 4 | | | | | safety and effectiveness information |
| 5 | | 6 | | 7 | 8 | | | 510 (k) summary attached 510 (k) statement | | | |
| Information on devices to which substantial equivalence is claimed (if known) | | | | | | | | | | | |
| IIIIOIIII | | | | | | | | | Manufacturer | | |
| | | | | | | | | | | | |
| 1 | | | | 1 | | | | | | 1 | |
| 2 | | | | 2 | | | | | | 2 | |
| 3 | | | | 3 | | | | | | 3 | |
| 4 | | | | 4 | | | | | | 4 | |
| 5 | | | | 5 | | | | | | 5 | |
| 6 | | | | 6 | | | | | | 6 | |
| 050 | ΓΙΟΝ F | | DDODUOT. | 11.5 | ORMATION - API | DI IOATIC | • | -0 AL | _ | | ATIONS |
| Comm | on or usual name or c | class | | | | | | | | | |
| Tr | ade or Proprietary or | Mod | del Name for This Devic | ce | | | | | , | Model N | Number |
| 1 | | | | | | 1 | | | | | |
| 2 | | | | | | 2 | | | | | |
| 3 | 3 | | | | | | 3 | | | | |
| 4 | | | | | | | | | 4 | | |
| 5 | | | | | | | | | 5 | | |
| FDA d | ocument numbers of | all p | prior related submission | ns (i | regardless of outcom | ne) | | IL | | | _ |
| 1 | | 2 | | 3 | | 4 | | | | 5 | 6 |
| 7 | | 8 | | 9 | | 10 | | | | 11 | 12 |
| Data I | Data Included in Submission Laboratory Testing Animal Trials Human Trials | | | | | | | | | | |
| | TION G | | | | SSIFICATION - AI | PPLICAT | ON | | | | CATIONS |
| Produ | ct Code C.F | F.R. | Section (if applicable) | | | | | Devic | | | _ |
| Classi | fication Panel | | | | | | | $\dashv \sqcup$ | Clas | ss I | Class II |
| | | | | | | Class III Unclassified | | | | | |
| Indications (from labeling) | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |
| | | | | | | | | | | | |

FORM FDA 3514 (12/03) PAGE 3 OF 5 PAGES

| Note: Submission of this in 2891a Device Establish | FDA Document Number (if known) | | | | | | | |
|--|--|---------------|--|---------|-------------------|-------------|--|--|
| SECTION H MANUFACTURING / PACKAGING / ST Original FDA Establishment Registration Number Company / Institution Name | | | ERILIZATION SITES RELATING TO A SUBMISSION Manufacturer Contract Sterilizer Contract Manufacturer Repackager / Relabeler Establishment Registration Number | | | | | |
| Division Name (if applicate Street Address | Phone Number (including area code) () FAX Number (including area code) () | | | | | | | |
| City | | | State / Province | | ZIP Code | Country | | |
| Contact Name | | Contact Title | | | Contact E-mail Ac | ddress | | |
| Original Add Delete Company / Institution Name | | | Manufacturer Contract Sterilizer Contract Manufacturer Repackager / Relabeler Establishment Registration Number | | | | | |
| Division Name (if applicat | Phone Number (including area code) () | | | | | | | |
| Street Address City | FAX Number (including area code) () State / Province ZIP Code Country | | | | | | | |
| Contact Name | Contact E-mail Address | | | | | | | |
| Original Add Delete Company / Institution Name | | | Manufacturer Contract Sterilizer Contract Manufacturer Repackager / Relabeler Establishment Registration Number | | | | | |
| Division Name (if applicated applicated street Address | Phone Number (including area code) () FAX Number (including area code) () | | | | | | | |
| City | State / Province | | ZIP Code | Country | | | | |
| Contact Name Contact Title | | | 1 | | Contact E-mail Ac | l Idress | | |

FORM FDA 3514 (12/03) PAGE 4 OF 5 PAGES

| SECTION I UTILIZATION OF STANDARDS | | | | | | | |
|--|---------------|---------------------------|-----------------|---------|------|--|--|
| Note: Complete this section if your application or submission cites standards or includes a "Declaration of Conformity to a Recognized Standard" statement. | | | | | | | |
| 1 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| 2 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| 3 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| 4 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| 5 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| 6 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| 7 | Standards No. | Standards Organization | Standards Title | Version | Date | | |
| | I. | | | | | | |

Public reporting burden for this collection of information is estimated to average 0.5 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Please include any additional standards to be cited on a separate page.

Food and Drug Administration CDRH (HFZ-342) 9200 Corporate Blvd. Rockville, MD 20850

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control

FORM FDA 3514 (12/03) PAGE 5 OF 5 PAGES